KR19990085303A - Skin whitening material - Google Patents
Skin whitening material Download PDFInfo
- Publication number
- KR19990085303A KR19990085303A KR1019980017641A KR19980017641A KR19990085303A KR 19990085303 A KR19990085303 A KR 19990085303A KR 1019980017641 A KR1019980017641 A KR 1019980017641A KR 19980017641 A KR19980017641 A KR 19980017641A KR 19990085303 A KR19990085303 A KR 19990085303A
- Authority
- KR
- South Korea
- Prior art keywords
- diene
- serena
- skin
- skin whitening
- preparation example
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 피부 미백 효과를 갖는 의약품 및 화장료로 사용할 수 있게 된 피부 미백제에 관한 것으로, 특히 세리나-4(14),7(11)-디엔-8-온을 유효 성분으로 하여 안전하고 뛰어난 피부 미백 효과를 갖게 된 것이다.The present invention relates to a skin whitening agent that can be used as a medicine and cosmetics having a skin whitening effect, and in particular, it is safe and excellent skin whitening using Serena-4 (14), 7 (11) -diene-8-one as an active ingredient. It will have an effect.
Description
본 발명은 피부 미백 효과를 갖는 의약품 및 화장료로 사용할 수 있게 된 피부 미백제에 관한 것으로, 특히 기미나 주근깨 개선 및 피부 미백제로서 멜라닌 생성 억제 효과가 우수한 세스퀴테르펜의 일종인 세리나-4(14),7(11)-디엔-8-온을 함유하는 피부 미백제에 관한 것이다.The present invention relates to a skin whitening agent that can be used as a medicine and cosmetics having a skin whitening effect, in particular, serena-4 (14), which is a kind of sesquiterpene excellent in improving melanin and freckles and inhibiting melanin production as a skin lightening agent. A skin whitening agent containing 7 (11) -diene-8-one.
일반적으로 사람의 피부색은 피부내 멜라닌의 농도와 분포에 따라 유전적으로 결정되나, 태양 자외선이나 피로, 스트레스 등의 환경적 또는 생리적 조건에 의해서도 영향을 받는데, 상기 멜라닌은 아미노산의 일종인 티로신에 티로시나제(tyrosinase)라는 효소가 작용하여 도파, 도파퀴논으로 바뀐 후 비효소적인 산화반응을 거쳐 만들어 진다.In general, the skin color of a person is genetically determined by the concentration and distribution of melanin in the skin, but is also affected by environmental or physiological conditions such as ultraviolet rays, fatigue, stress, melanin is a type of amino acid tyrosine tyrosinase ( tyrosinase) acts as a dopa and a dopaquinone and then undergoes non-enzymatic oxidation.
이와 같이 멜라닌이 생성되는 경로는 알려져 있으나, 티로시나제가 작용하는 이전 단계인 멜라닌 합성을 유도하는 메카니즘이 무엇인지에 대해서는 아직도 자세히 밝혀지지 않고 있다.As such, melanin production pathways are known, but the mechanisms that induce melanin synthesis, the previous stages of tyrosinase action, are still unknown.
따라서 종래에는 하이드로퀴논이나 아스콜빈산(ascorbic acid), 코지산(kojic acid), 글루타치온(glutathione) 등과 같이 티로시나제 저해 활성을 갖는 물질을 연고나 화장료에 배합하여, 피부 미백이나 기미, 주근깨 개선의 목적에 사용하여 왔다.Therefore, conventionally, a substance having tyrosinase inhibitory activity, such as hydroquinone, ascorbic acid, kojic acid, glutathione, and the like, is incorporated into ointments or cosmetics to improve skin whitening, blemishes, and freckles. Has been used.
그러나, 이와 같은 피부 미백제는 피부에 자극을 유발하거나 제품 안정성이 좋지 못하여 사용이 제한되고, 그 효과도 미약한 단점이 있었다.However, such a skin lightening agent causes irritation to the skin or poor product stability, thereby limiting its use and having a weak effect.
이에 본 발명은 상기한 문제점을 해소하기 위한 것으로, 강력한 멜라닌 생성 억제 효과를 가지면서 사용상의 문제점이 적은 피부 미백제를 제공함에 그 목적이 있다.Accordingly, the present invention is to solve the above problems, and has an object of providing a skin whitening agent having a strong melanin production inhibitory effect and less use problems.
상기한 목적을 달성하기 위한 본 발명의 피부 미백제는, 하기 화학식 1의 세리나-4(14),7(11)-디엔-8-온을 함유하는 것을 특징으로 하는 것이다.The skin lightening agent of the present invention for achieving the above object is characterized in that it contains Cerina-4 (14), 7 (11) -diene-8-one of formula (1).
상기 세리나-4(14),7(11)-디엔-8-온은 항염효과[Chem. Pharm. Bull.,27(12),2954,1979], 항치매효과(일본공개특허 JP09094452)등의 연구가 보고되어 있으나, 본 발명과는 완전히 구별된다.The serina-4 (14), 7 (11) -diene-8-one has an anti-inflammatory effect [Chem. Pharm. Bull., 27 (12), 2954, 1979] and anti-dementia effects (Japanese Patent Laid-Open No. JP09094452) have been reported, but are completely distinguished from the present invention.
따라서, 상기 세리나-4(14),7(11)-디엔-8-온은 탄소수 15개로 이루어진 유기화합물로서 여러 문헌에 기재된 공지의 물질로서, 미생물이나 식물, 동물 등의 정유물에 존재하는 것을 사용할 수 있다.Accordingly, the serena-4 (14), 7 (11) -diene-8-one is an organic compound having 15 carbon atoms, which is a known substance described in various literatures, and is present in essential oils such as microorganisms, plants, and animals. Can be used.
이를 테면 백출이나, 창출, 적출, 노루귀, 자금우, 세신, 등골나무 등에 함유된 세리나-4(14),7(11)-디엔-8-온을 추출하여 본 발명의 피부 미백제로 사용할 수 있는 것이다.For example, it is possible to extract serena-4 (14), 7 (11) -diene-8-one contained in whitening, creation, extraction, roe deer, golden woo, sessin, liana, etc., and to use it as a skin lightening agent of the present invention. .
상기한 바와 같이 본 발명은 세리나-4(14),7(11)-디엔-8-온을 함유한 것을 특징으로 하는 피부 미백제를 제공하기 위한 것이고, 상기 세리나-4(14),7(11)-디엔-8-온은 세스퀴테르펜의 일종으로 자연에서 얻을 수 있는 천연 유기화합물이다.As described above, the present invention is to provide a skin whitening agent, which contains serena-4 (14), 7 (11) -diene-8-one, and the serena-4 (14), 7 (11). ) -Dien-8-one is a sesquiterpene, a natural organic compound that can be obtained from nature.
상기 세리나-4(14),7(11)-디엔-8-온은 특히 생약재로 시판되는 백출, 창출, 적출, 노루귀, 자금우, 세신, 등골나무 등의 식물로부터 추출하는 것이 바람직하며, 상기 식물 종류에만 한정되는 것은 아니다.The serena-4 (14), 7 (11) -diene-8-one is particularly preferably extracted from plants such as baekrye, creation, extraction, hepatica, fern, sessin, wisteria, etc. It is not limited to kind.
이러한 식물로부터 세리나-4(14),7(11)-디엔-8-온을 추출하는 방법은 공지된 여러 방법을 사용할 수 있는데, 일례로서 잘게 분쇄한 식물 분쇄물에서 유기 용매를 사용하여 세리나-4(14),7(11)-디엔-8-온을 추출하고 건조시킨 후, 물에 현탁시킨 다음 헥산 등을 가하여 액-액 추출하고 이를 칼럼크로마토그라피와 고속액체크로마토그라피로 순수한 세리나-4(14),7(11)-디엔-8-온을 얻는 방법을 들 수 있다.Extraction of serena-4 (14), 7 (11) -diene-8-one from such plants can be carried out using a variety of known methods, for example, by using an organic solvent in a finely ground plant mill. 4 (14), 7 (11) -diene-8-one was extracted and dried, suspended in water, followed by hexane and the like, followed by liquid-liquid extraction, which was purified by column chromatography and high performance liquid chromatography. (14), 7 (11) -diene-8-one is obtained.
이와 같이 추출된 세리나-4(14),7(11)-디엔-8-온을 쥐의 멜라노마 세포(B-16 melanoma cell)에 처리하였을 때, 매우 강력한 멜라닌 합성 저해 효과를 나타내었으며, 이를 피부 외용 연고나 로션같은 여러 화장료에 함유시켜 사람의 피부에 도포하였을 때 피부 미백 효과가 매우 우수하였고, 또한 어떤 부작용도 발생하지 않아 안전하고 효과가 매우 뛰어난 기미나 주근깨 개선제 및 피부 미백제로 사용할 수 있음을 알 수 있었다.When the extracted serena-4 (14), 7 (11) -diene-8-one was treated to rat melanoma cells (B-16 melanoma cells), it showed a very strong melanin synthesis inhibitory effect. It is used in various cosmetics such as external skin ointments and lotions, and when applied to human skin, the skin whitening effect is very good.It does not cause any side effects, and it can be used as a safe and effective anti-freckle and skin whitening agent. And it was found.
피부 외용 연고나 화장료 제조시에 함유되는 세리나-4(14),7(11)-디엔-8-온의 함량은 건조 중량으로 0.000001-10.0중량%를 사용하는 것이 바람직하나, 0.001중량%이하로 함유시켰을 때 피부 미백 효과가 뛰어나지 않았고, 1.0중량%이상으로 함유시켰을 때 함유량의 증가에 따라 뚜렷한 효과의 증가가 나타나지 않았으므로, 세리나-4(14),7(11)-디엔-8-온의 함량을 0.001-1.0중량%로 하는 것이 더욱 바람직하다 할 것이다.The amount of serina-4 (14), 7 (11) -diene-8-one in the skin ointment or cosmetic preparation is preferably 0.000001-10.0% by weight in dry weight, but not more than 0.001% by weight. When contained, the skin whitening effect was not excellent, and when contained at 1.0 wt% or more, there was no apparent increase in effect with the increase of the content. Therefore, the content of Sena-4 (14), 7 (11) -diene-8-one It is more preferable to make the content 0.001-1.0% by weight.
다음으로 실시예와 실험예, 제조예에 의거하여 본 발명을 더욱 자세히 설명하고자 하며, 본 발명이 이 실시예에만 한정되는 것이 아님을 밝혀둔다.Next, the present invention will be described in more detail based on Examples, Experimental Examples, and Preparation Examples, and the present invention is not limited only to this Example.
실시예 1Example 1
백출을 구입하여 분쇄물 100g을 100% n-헥산용매 500ml에 넣고, 냉각콘덴서가 달린 환류 추출기에서 3시간 끓여 추출한 다음, 300메쉬 여과포로 여과한 후 잔사를 같은 방법으로 1회 더 추출하였다. 각각의 추출액을 합하여 상온에서 화트만(Whatman) 2번 여과지로 여과하여 불용성 물질을 제거한 후, 냉각 콘덴서가 달린 증류장치에서 60℃로 감압농축한 후 정제수 300ml에 현탁한 다음 헥산 300ml를 가하고 잘 흔들어 헥산 용해물을 얻었다. 이 헥산 용해물을 실리카겔칼럼에서 크로마토그라피하여 유효성분을 함유하는 분획 450mg을 얻었다. 이를 다시 고속액체크로마토그라피로 정제하여 세리나-4(14),7(11)-디엔-8-온을 210mg 분리하였다.Purified 100 g of the pulverized product was put in 500 ml of 100% n-hexane solvent, boiled for 3 hours in a reflux extractor equipped with a cooling capacitor, filtered through a 300 mesh filter cloth, and the residue was extracted once more in the same manner. Each extract was combined and filtered using Whatman No. 2 filter paper at room temperature to remove insoluble matters. The mixture was concentrated under reduced pressure at 60 ° C. in a distillation apparatus equipped with a cooling condenser, suspended in 300 ml of purified water, and then shaken well with 300 ml of hexane. Hexane lysate was obtained. This hexane lysate was chromatographed on a silica gel column to obtain 450 mg of a fraction containing the active ingredient. This was further purified by high performance liquid chromatography to separate 210 mg of serena-4 (14), 7 (11) -diene-8-one.
분리된 세리나-4(14),7(11)-디엔-8-온의 프로토 NMR 스펙트럼을 하기 표 1에 나타내었고, 매스 스펙트럼을 하기 표 2에 나타내었다.The proto NMR spectra of the separated serina-4 (14), 7 (11) -diene-8-one are shown in Table 1 below, and the mass spectra are shown in Table 2 below.
실시예 2Example 2
백출을 구입하여 분쇄물 100g을 100% 에탄올 용매 500ml에 넣고, 상기 실시예 1과 동일한 방법으로 실시하여 세리나-4(14),7(11)-디엔-8-온을 155mg 얻었다.100 g of a pulverized product was purchased and 500 ml of 100% ethanol solvent was put in the same manner as in Example 1 to obtain 155 mg of serina-4 (14), 7 (11) -diene-8-one.
실시예 3Example 3
백출을 구입하여 분쇄물 100g을 100% 클로로포름 용매 500ml에 넣고, 상기 실시예 1과 동일한 방법으로 실시하여 세리나-4(14),7(11)-디엔-8-온을 175mg 얻었다.100 g of a pulverized product was purchased and 100 ml of 100% chloroform solvent was put in the same manner as in Example 1 to obtain 175 mg of Serina-4 (14), 7 (11) -diene-8-one.
실시예 4Example 4
백출을 구입하여 분쇄물 100g을 100% 카프릭/카프릴릭 트리에스터 500ml에 넣고, 냉각 콘덴서가 달린 환류 추출기에서 3시간 끓여 추출한 다음, 300메쉬 여과포로 여과한 후, 상온에서 화트만 2번 여과지로 여과하여 불용성물질을 제거한 후, 고속액체크로마토그라피를 사용하여 세리나-4(14),7(11)-디엔-8-온을 정량한 결과, 세리나-4(14),7(11)-디엔-8-온의 함량이 분쇄물 100g당 280mg 이었다.Purified 100 g of crushed powder was put into 500 ml of 100% capric / caprylic triester, boiled for 3 hours in a reflux extractor equipped with a cooling condenser, filtered with 300 mesh filter paper, and then filter paper 2 times at room temperature. After removing the insoluble substance by filtration with Sera-4 (14), 7 (11) -diene-8-one using high-performance liquid chromatography, Serena-4 (14), 7 (11)- The content of diene-8-one was 280 mg per 100 g of milled product.
실시예 5Example 5
창출 분쇄물 100g을 n-헥산 용매 500ml에 넣고, 상기 실시예 1과 동일한 방법으로 실시하여 세리나-4(14),7(11)-디엔-8-온을 170mg 얻었다.100 g of the resulting pulverized product was put in 500 ml of n-hexane solvent, and the same procedure as in Example 1 was carried out to obtain 170 mg of serena-4 (14), 7 (11) -diene-8-one.
실시예 6Example 6
적출 분쇄물 100g을 n-헥산 용매 500ml에 넣고, 상기 실시예 1과 동일한 방법으로 실시하여 세리나-4(14),7(11)-디엔-8-온을 150mg 얻었다.100 g of the extracted pulverized product was put in 500 ml of n-hexane solvent, and the same procedure as in Example 1 was carried out to obtain 150 mg of serina-4 (14), 7 (11) -diene-8-one.
실시예 7Example 7
노루귀 분쇄물 100g을 n-헥산 용매 500ml에 넣고, 상기 실시예 1과 동일한 방법으로 실시하여 세리나-4(14),7(11)-디엔-8-온을 170mg 얻었다.100 g of pulverized pulverum was put in 500 ml of a n-hexane solvent, and was carried out in the same manner as in Example 1 to obtain 170 mg of serena-4 (14), 7 (11) -diene-8-one.
실시예 8Example 8
자금우 분쇄물 100g을 n-헥산 용매 500ml에 넣고, 상기 실시예 1과 동일한 방법으로 실시하여 세리나-4(14),7(11)-디엔-8-온을 140mg 얻었다.100 g of sorghum pulverized product was put in 500 ml of n-hexane solvent, and the same procedure as in Example 1 was carried out to obtain 140 mg of serina-4 (14), 7 (11) -diene-8-one.
실시예 9Example 9
세신 분쇄물 100g을 n-헥산 용매 500ml에 넣고, 상기 실시예 1과 동일한 방법으로 실시하여 세리나-4(14),7(11)-디엔-8-온을 150mg 얻었다.100 g of sericin crushed product was put in 500 ml of n-hexane solvent, and it carried out by the same method as Example 1, and obtained 150 mg of serina-4 (14), 7 (11) -diene-8-one.
실시예 10Example 10
등골나무 분쇄물 100g을 n-헥산 용매 500ml에 넣고, 상기 실시예 1과 동일한 방법으로 실시하여 세리나-4(14),7(11)-디엔-8-온을 165mg 얻었다.100 g of the rattan crushed product was put in 500 ml of n-hexane solvent, and the same procedure as in Example 1 was carried out to obtain 165 mg of serina-4 (14), 7 (11) -diene-8-one.
실험예 1Experimental Example 1
상기 실시예 1에 따라 얻어진 세리나-4(14),7(11)-디엔-8-온을 쥐의 멜라노마 세포의 배양액에 첨가하여 세포 수준에서의 미백 효과를 실험하였다(Lotan R., Lotan D. Cancer Res. 40:3345-3350, 1980).Serena-4 (14), 7 (11) -diene-8-one obtained according to Example 1 was added to the culture of mouse melanoma cells to test the whitening effect at the cellular level (Lotan R., Lotan D. Cancer Res. 40: 3345-3350, 1980).
우선 세리나-4(14),7(11)-디엔-8-온을 최종 농도가 1μg/ml, 5μg/ml, 20μg/ml가 되도록 하고, 하이드로퀴논 수용액과 함께 각각 B-16 멜라노마 세포의 배양배지에 첨가하여 3일간 배양한 후, 세포들을 트립신(trypsin) 처리하여 배양용기로부터 떼어내 원심 분리한 후 멜라닌을 추출하였다. 이것에 수산화나트륨 용액(1N농도) 1ml를 가하여 10분간 끓여 멜라닌을 녹이고 분광 광도계를 이용, 400nm에서 흡광도를 측정하여 생성된 멜라닌의 양을 단위 세포수당(106cell)의 흡광도로 나타내는 방법으로 수행하였으며, 대조군에 대한 상대적인 멜라닌 생성량을 저해율(%)로 계산하고 결과를 하기 표 3에 나타내었다. 여기서 세리나-4(14),7(11)-디엔-8-온은 "AT-1"이라 표기하였고, 3회 반복 실험한 결과이다.First, serina-4 (14), 7 (11) -diene-8-one was brought to a final concentration of 1 μg / ml, 5 μg / ml, and 20 μg / ml, and the aqueous solution of B-16 melanoma cells with aqueous hydroquinone solution, respectively. After culturing for 3 days by adding to the culture medium, cells were trypsinized, separated from the culture vessel, centrifuged, and melanin was extracted. To this, 1 ml of sodium hydroxide solution (1N concentration) was added, boiled for 10 minutes to dissolve the melanin, and the absorbance was measured at 400 nm by using a spectrophotometer to measure the amount of melanin produced as the absorbance of 10 6 cells. And, the melanin production relative to the control group was calculated as the inhibition rate (%) and the results are shown in Table 3 below. Here, serena-4 (14), 7 (11) -diene-8-one is designated as "AT-1", and is the result of three repeated experiments.
상기 표 3의 결과에서 볼 수 있듯이 실시예에 따라 얻어진 세리나-4(14),7(11)-디엔-8-온은 기존에 알려진 미백 물질인 하이드로퀴논과 비교할 때 배양된 쥐의 멜라노마 세포에 대하여 대등한 멜라닌 생성 억제능이 있음을 알 수 있다. 또한 하이드로퀴논은 저농도에서 강력한 멜라닌 생성 억제능을 가지지만 세포 독성이 심해 1μg/ml이상에서는 실험을 할 수 없는 것에 반하여, 세리나-4(14),7(11)-디엔-8-온은 20μg/ml 농도에서도 세포 독성을 나타내지 않으면서 하이드로퀴논보다 높은 멜라닌 생성 억제 효과를 갖는다.As can be seen from the results in Table 3, serena-4 (14), 7 (11) -diene-8-one obtained according to the embodiment is cultured mouse melanoma cells as compared to hydroquinone, a known whitening substance. It can be seen that there is a comparable inhibitor of melanogenesis. In addition, hydroquinone has strong melanin production inhibitory ability at low concentrations, but the cytotoxicity is so severe that it cannot be tested at 1 μg / ml or more, whereas serina-4 (14), 7 (11) -diene-8-one is 20 μg / It has a higher melanin inhibitory effect than hydroquinone without showing cytotoxicity in ml concentration.
이하 세리나-4(14),7(11)-디엔-8-온을 함유하는 화장료의 처방예를 제조예에 의해 나타내었다.The preparation example of the cosmetics containing serina-4 (14), 7 (11) -diene-8-one below is shown by the manufacture example.
제조예 1 및 비교예 1Preparation Example 1 and Comparative Example 1
세리나-4(14),7(11)-디엔-8-온을 함유하는 피부 외용연고 처방예는 다음 표 4와 같다.Examples of prescription external skin ointments containing serena-4 (14), 7 (11) -diene-8-one are shown in Table 4 below.
제조예 2 및 비교예 2Preparation Example 2 and Comparative Example 2
세리나-4(14),7(11)-디엔-8-온을 함유하는 화장료중 크림의 처방예는 다음 표 5와 같다.Formulation examples of the cream in the cosmetic containing serena-4 (14), 7 (11) -diene-8-one are shown in Table 5 below.
제조예 3 및 비교예 3Preparation Example 3 and Comparative Example 3
세리나-4(14),7(11)-디엔-8-온을 함유하는 화장료중 유연화장수의 처방예는 다음 표 6과 같다.Prescription examples of flexible cosmetics in cosmetics containing serena-4 (14), 7 (11) -diene-8-one are shown in Table 6 below.
제조예 4 및 비교예 4Preparation Example 4 and Comparative Example 4
세리나-4(14),7(11)-디엔-8-온을 함유하는 화장료중 엣센스의 처방예는 다음표 7과 같다.Prescription examples of essences in cosmetics containing serena-4 (14), 7 (11) -diene-8-one are shown in Table 7 below.
제조예 5 및 비교예 5Preparation Example 5 and Comparative Example 5
세리나-4(14),7(11)-디엔-8-온을 함유하는 화장료중 팩의 처방예는 다음 표 8과 같다.Prescription examples of packs in cosmetics containing serena-4 (14), 7 (11) -diene-8-one are shown in Table 8 below.
제조예 6 및 비교예 6Preparation Example 6 and Comparative Example 6
세리나-4(14),7(11)-디엔-8-온을 함유하는 화장료중 영양화장수의 처방예는 다음 표 9와 같다.Prescription examples of nutrient cosmetics in cosmetics containing serena-4 (14), 7 (11) -diene-8-one are shown in Table 9 below.
실험예 2Experimental Example 2
건강한 남녀 20명을 선정하여 양팔의 하박부에 직경 7mm크기의 구멍이 6개씩 2줄로 파인 알루미늄 호일을 붙이고, 팔에서 10cm 떨어진 거리에서 ORIEL solar simulator 1000W를 사용하여 60mJ/cm2의 광량을 조사하였다. 조사전에 70% 에탄올 수용액으로 조사 부위를 잘 세척하였다. 조사하기 3일전부터 조사후 3주째까지 1일 2회씩 제조예 1-6 및 비교예 1-6에 따라 제조된 기제를 한 쌍으로 같은 줄에 도포하였다(제조예 5 및 비교예 5의 팩 처방의 경우 도포한 다음 15분후에 떼어내었다).Twenty healthy men and women were selected to attach aluminum foil in two rows of 6 holes with a diameter of 7 mm in the lower part of both arms, and 60mJ / cm 2 light was irradiated using ORIEL solar simulator 1000W at a distance of 10 cm from the arm. . The irradiation site was washed well with 70% ethanol aqueous solution before irradiation. The bases prepared according to Preparation Example 1-6 and Comparative Example 1-6 were applied to the same line twice a day from 3 days before irradiation to 3 weeks after irradiation (pack prescription of Preparation Example 5 and Comparative Example 5). In case of application, it was removed after 15 minutes).
각각에 대하여 제조예와 비교예의 색소침착도를 육안으로 판정하고, 제조예가 비교예에 비하여 색소침착을 억제한 정도를 효과있음, 차이없음의 2단계로 평가하였으며, 그 결과는 다음 표 10과 같다.For each, the pigmentation degree of the preparation example and the comparative example were visually determined, and the degree to which the preparation example suppressed the pigmentation was evaluated in two stages of effective and no difference compared to the comparative example, and the results are shown in Table 10 below. .
상기 표 10의 결과에서 볼 수 있듯이, 제조예 1-6에 따라 제조된 세리나-4(14),7(11)-디엔-8-온을 함유하는 연고 및 화장료는 피시험자 20명 중에서 최소 10명 이상에 대하여 미백 효과를 나타내었으며, 특히 많은 양의 세리나-4(14),7(11)-디엔-8-온이 적용된 제조예 1에서는 70%가 색소 침착 저해 효과를 보이고, 피부내에서 어떤 부작용도 나타나지 않아, 세리나-4(14),7(11)-디엔-8-온이 안전하고 효과가 매우 뛰어난 기미나 주근깨 개선 또는 피부미백제임을 알 수 있다.As can be seen from the results in Table 10, ointments and cosmetics containing serena-4 (14), 7 (11) -diene-8-one prepared according to Preparation Example 1-6 were at least 10 out of 20 subjects. It showed whitening effect on more than one person. Especially, in Preparation Example 1, in which a large amount of serena-4 (14), 7 (11) -diene-8-one was applied, 70% showed pigmentation inhibitory effect, There are no side effects, suggesting that Serena-4 (14), 7 (11) -diene-8-one is a safe and highly effective blemish or freckles improver or skin whitening agent.
상술한 바와 같이, 본 발명에 따른 세리나-4(14),7(11)-디엔-8-온을 유효 성분으로 하는 피부 미백제는 피부에 부작용이 없어 안전하고 또한 뛰어난 기미나 주근깨 개선 및 피부 미백 효과를 가지는 것이다.As described above, the skin whitening agent containing Serena-4 (14), 7 (11) -diene-8-one as an active ingredient according to the present invention has no side effects on the skin and is safe and has excellent blemishes and freckles, and skin whitening. It has an effect.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019980017641A KR100453217B1 (en) | 1998-05-15 | 1998-05-15 | Skin whitener |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019980017641A KR100453217B1 (en) | 1998-05-15 | 1998-05-15 | Skin whitener |
Publications (2)
Publication Number | Publication Date |
---|---|
KR19990085303A true KR19990085303A (en) | 1999-12-06 |
KR100453217B1 KR100453217B1 (en) | 2005-07-07 |
Family
ID=37303316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019980017641A KR100453217B1 (en) | 1998-05-15 | 1998-05-15 | Skin whitener |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100453217B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020044266A (en) * | 2000-12-05 | 2002-06-15 | 양봉철 | Skin protective cosmetic composition comprising extracts from complex crude drugs |
KR100661811B1 (en) * | 2006-01-02 | 2006-12-28 | 주식회사 엘지생활건강 | Miniemulsion cosmetic composition containing selina-4(14),7(11)-dien-8-one |
KR100825929B1 (en) * | 2006-11-09 | 2008-04-28 | 한국콜마 주식회사 | Oriental medicine plant extract having whitening effect, manufacturing method thereof and cosmetics comprising the oriental medicine plant extract |
KR101864719B1 (en) | 2017-02-21 | 2018-06-05 | 김수현 | Composition for prevention and treatment of osteoporosis comprising the extract of medicinal herb mixture |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100805662B1 (en) | 2006-10-02 | 2008-02-21 | 한경택 | Extraction and purification of an effective component from atractylodis rhizoma |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3660692B2 (en) * | 1993-11-18 | 2005-06-15 | 株式会社ノエビア | Tyrosinase biosynthesis inhibitor and whitening agent comprising the same |
JPH08175956A (en) * | 1994-12-27 | 1996-07-09 | Kao Corp | Skin-beautifying cosmetic |
JPH0948704A (en) * | 1995-08-04 | 1997-02-18 | Earth Chem Corp Ltd | Humectant |
JP2816664B2 (en) * | 1996-01-11 | 1998-10-27 | ノブヨシ ハギノ | Anti-dementia agent |
JPH101438A (en) * | 1996-06-11 | 1998-01-06 | Noevir Co Ltd | Preparation for external use for skin |
-
1998
- 1998-05-15 KR KR1019980017641A patent/KR100453217B1/en not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020044266A (en) * | 2000-12-05 | 2002-06-15 | 양봉철 | Skin protective cosmetic composition comprising extracts from complex crude drugs |
KR100661811B1 (en) * | 2006-01-02 | 2006-12-28 | 주식회사 엘지생활건강 | Miniemulsion cosmetic composition containing selina-4(14),7(11)-dien-8-one |
KR100825929B1 (en) * | 2006-11-09 | 2008-04-28 | 한국콜마 주식회사 | Oriental medicine plant extract having whitening effect, manufacturing method thereof and cosmetics comprising the oriental medicine plant extract |
KR101864719B1 (en) | 2017-02-21 | 2018-06-05 | 김수현 | Composition for prevention and treatment of osteoporosis comprising the extract of medicinal herb mixture |
Also Published As
Publication number | Publication date |
---|---|
KR100453217B1 (en) | 2005-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101418986B1 (en) | Composition for promoting collagen synthesis and cosmetics comprising the same | |
KR20090131767A (en) | Cosmetics composition for skin whitening | |
KR100454736B1 (en) | Composition for skin whitening containing veratramine | |
KR100453217B1 (en) | Skin whitener | |
KR100190992B1 (en) | A skin whitening composition containing extracts of asparagus cochinchinensis and tyrosinase inhibitor | |
KR100789632B1 (en) | Cosmetic for skin whitening containing a herb extract with inhibitory activity of melanin formation | |
JP4772190B2 (en) | Skin lightening agent | |
KR20020029182A (en) | Cosmetic composition containing Veratrum nigrum L. extracts and Potentilla chinensis Ser. extracts | |
KR20050092313A (en) | Skin whitening cosmetic containing a herb extract with inhibitory activity of melanin formation | |
KR100530669B1 (en) | Cosmetic Compositions Comprising Lactate and Glycyrrhiza Uralensis Extracts for Skin Whitening | |
KR100466379B1 (en) | Composition for skin whitening | |
KR100789634B1 (en) | Cosmetic for skin whitening containing a herb extract with inhibitory activity of melanin formation | |
KR20040087644A (en) | Cosmetic Composition Comprising Pyrus communis L. Extract for Skin Whitening | |
KR20020029181A (en) | Cosmetic composition containing Liquidambar taiwaniana Hance extracts and Cynanchum atratum Bunge extracts | |
KR100509848B1 (en) | Composition for skin whitening | |
KR19990048305A (en) | Skin Whitening Composition | |
KR100431271B1 (en) | Composition for skin whitening containing Arecoline | |
KR20050092314A (en) | Skin whitening cosmetic containing a herb extract with inhibitory activity of melanin formation | |
KR20040059005A (en) | Skin Whitening Cosmetic containing a herb extract with inhibitory activity of melanin formation | |
KR0180689B1 (en) | Skin whitening composition | |
KR20020029184A (en) | Cosmetic composition containing Acalypha australis L. extracts and Pterocarya stenoptera DC extracts | |
KR100770124B1 (en) | Composition for skin whitening containing machilin-A | |
KR100724168B1 (en) | Cosmetic for skin whitening containing a herb extract with inhibitory activity of melanin formation | |
KR101791488B1 (en) | Composition of skin external application for alleviating stimulation caused from ultraviolet ray containing Oldenlandia Diffusa Willd extracts | |
KR20040059007A (en) | Skin Whitening Cosmetic containing a herb extract with inhibitory activity of melanin formation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120914 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20130913 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20140917 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20150917 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20160919 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20170928 Year of fee payment: 14 |
|
EXPY | Expiration of term |